Total amount: € 0,00
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,236
Online ISSN 1827-1669
Terlizzi M. E. 1, Costa C. 1, Astegiano S. 1, Sidoti F. 1, Vendrame R. 1, Segoloni G. P. 2, Bergallo M. 1, Cavallo R. 1
1 Department of Public Health and Microbiology Virology Unit, University of Turin, Turin, Italy
2 Renal Transplant Unit Department of Internal Medicine, University of Turin, Turin, Italy
Aim. Human Cytomegalovirus (HCMV) is a relevant pathogen in transplant recipients, particularly in the first three months post-transplantation. The use of antiviral prophylaxis and pre-emptive therapy is able to reduce incidence of HCMV infection and disease. The incidence of HCMV infection and disease in renal transplant recipients in the first 100 days post-transplantation was investigated, in relation with HCMV serological matching and therapeutic management.
Methods. Incidence of HCMV infection in the first 100 days post-transplantation was evaluated by pp65-antigenemia in 165 patients on a total number of 1 241 clinical samples. Patients were divided in four groups according to donor/recipient serological matching: D–/R– (low risk of HCMV disease), D–/R+ and D+/R+ (intermediate risk) and D+/R– (high risk). Antiviral strategy (prophylaxis in high risk group; pre-emptive therapy in intermediate risk group, no therapy in low risk group) and immunosuppressive protocol were recorded.
Results. Incidence of antigenemia-positivity was as follows: 0/3 D–/R– patients; 59/130 (45.4%) D+/R+; 5/16 (31.3%) D–/R+; 4/16 D+/R–. No significative difference was found between the four groups in terms of incidence of antigenemia-positivity in the first 100 days following transplantation. Antigenemia values >50 pp65-positive/2¥105 peripheral blood leukocytes (used to start pre-emptive therapy) were present in 18/130 (13.8%) D+/R+; 1/16 (6.2%) D+/R–; 0/16 D–/R+. Viral kinetics in patients with HCMV infection was described.
Conclusion. No significative difference was found in terms of incidence of HCMV infection in the first 100 days post-transplantation in relation to immunosuppressive protocol and serological matching, suggesting the appropriateness of antiviral strategies and viral monitoring adopted in this setting.
language: English, Italian